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Results

Background
Treatments for breast cancer vary from endocrine therapy,
chemotherapy, immunotherapy, to surgery. Dr. Symmans’s
lab works to determine the sensitivity to endocrine therapy
using metastatic breast cancer biomarkers. The lab has
developed an index to determine the sensitivity to endocrine
therapy (SETER/PR )1, which evaluates the gene expression of
breast cancer related hormone receptors. SETER/PR targets
18 genes correlating with estrogen and progesterone
receptors, ESR1 and PGR. The lab also included the
PI3Kges, which measures the expression of the PI3K
pathway activation due to mutations in PIK3CA.2 This
information can be used in clinical settings to determine if
endocrine therapy will be effective in treating breast cancer
patients. Different technology methods have been developed
to measure gene expressions. The lab used the Quantigene
Plex (QGP) platform3 (quantitative gene expression through
hybridization) to develop a 31 and 40 target gene panel.
QGP31 has 31 target genes and can detect the SETER/PR
index, while QGP40 has 9 additional target genes and is
able to detect both SETER/PR and PI3Kges. The Illumina
MiSeq platform (RNA sequencing) was used to develop
SET4, which includes both SETER/PR and PI3Kges.

Figure 1a. Linear regression (red, solid) plot of SETER/PR for QGP40 and
SET4 in comparison to the line of perfect agreement (blue, dotted).

Figure 1b. Linear regression (red, solid) plot of PI3Kges for QGP40 and
SET4 in comparison to the line of perfect agreement (blue, dotted).

Figure 1c. Linear regression (red, solid) plot of SETER/PR for QGP40 and
QGP31 in comparison to the line of perfect agreement (blue, dotted).

Figure 1d. Linear regression (red, solid) plot of SETER/PR for QGP31 and
SET4 in comparison to the line of perfect agreement (blue, dotted).

The aim of this study is to validate the calibration of each
platform’s measured index. By doing so, labs can provide
more consistent conclusions regarding patient’s sensitivity
regardless of the platform being used.

Methods
Formalin-fixed and paraffin-embedded (FFPE) breast cancer
tissue blocks (n=20) were collected from individual breast
cancer patients. The FFPE blocks were cut into 5 or 10
micron sections and extracted for RNA using Norgen FFPE
RNA Purification kit. The gene expression of each sample
was measured using 3 different platforms: The Affymetrix
QuantiGene 31-Plex (QGP31), 40-Plex (QGP40), and SET4.
QGP31 and QGP40 were measured using Luminex
MAGPIX, and SET4 was sequenced and measured on the
Illumina Miseq platform. The gene expression
measurements were input into an established script written
in the programming language R to calculate the SETER/PR
from all platforms and PI3Kges values from QGP40 and
SET4. The equations for SETER/PR index and PI3Kges index
are

where Ti denotes the log2 expression of the eighteen SET
biomarkers, Rj the log2 expression of the ten reference genes,
and Pi the log2 expression of the ten PI3Kges biomarkers.
These values were graphed against the same measurements
of other platforms. A line of best fit with the equation, R2
value, and concordance correlation coefficient (CCC) was
generated.

Discussion
SETER/PR is a reliable and robust analytical system to
accommodate the various platforms used in laboratory
molecular testing. Through the SETER/PR index
comparison of 20 individual breast cancer FFPE
derived RNA samples between QGP31, QGP40, and
SET4, SETER/PR was observed to be highly concordant
(CCC 0.727-0.977) between all three platforms. This is
also true with the PI3Kges index comparison between
QGP40 and SET4 (CCC 0.925). Index pairs involving
SET4 were less concordant than the QGP40-QGP30
pair. This is possibly due to the difference in assay
technology. The high concordance and R2 (0.9510.986) indicate that the index values could be
accurately calibrated between platforms. Equations
from the linear regression indicate that the SETER/PR for
QGP31-SET4 and QGP40-SET4 require larger
adjustments for standardization between platforms.

Conclusion
The high concordance for each index comparison
show that the calculated index of the platforms can be
comparable with calibration. Labs will be able to use
any platform to provide accurate conclusions on a
patient’s sensitivity to endocrine therapy. Future
direction of the study can be done with interlaboratory
testing of a larger cohort size using the adjusted
algorithm.
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